IN8BIO, INC.

INAB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001740279

SEC filings (opens in a new tab)

Insider trades, last 90 days

None

No open-market purchases or sales were filed in the last 90 days.

View insider trades

13F holders, Q2 2026

21

+2 vs. Q1 2026
Total value $5.35M

View 13F holders

Superinvestors holding INAB

0

None of the superinvestors held INAB at the end of Q2 2026.

See all holders

Price chart

Chart by TradingView (opens in a new tab)

Latest insider trades

Open-market purchases and sales by INAB insiders, newest first.

Insider trades
Filed (ET)	Trade date	Insider	Transaction	Shares	Avg price	Value	Shares after	Holding change	Filing
May 7, 20259:48 PM ET	May 2, 2025	BIOS Fund II, LP and 8 others10% Owner	PPurchaseCommon Stock · Derivative	+1.15M	–	–	2.43M	–	SEC
May 7, 20259:47 PM ET	May 2, 2025	BIOS Fund III NT, LP and 9 others10% Owner	PPurchaseCommon Stock · Derivative	+1.15M	–	–	2.43M	–	SEC
Oct 11, 20246:13 PM ET	Oct 4, 2024	BIOS Fund III NT, LP and 9 others10% Owner	PPurchaseCommon Stock · Derivative	+1.28M	–	–	709.04K	–	SEC
Oct 11, 20246:12 PM ET	Oct 4, 2024	BIOS Fund II, LP and 8 others10% Owner	PPurchaseCommon Stock · Derivative	+1.28M	–	–	709.04K	–	SEC
Oct 8, 2024	Oct 4, 2024	FAIRBAIRN EMILYDirector	PPurchaseCommon Stock · Derivative	+6.08M	–	–	3.04M	–	SEC

Top 5 13F holders, Q2 2026

The largest institutional positions in INAB at the end of Q2 2026.

Institutions holding INAB in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Alyeska Investment Group, L.P.	944,319	$1.33M	0.00%	00.0%	Unchanged
FRANKLIN RESOURCES INC	914,531	$1.29M	0.00%	00.0%	Unchanged
683 Capital Management, LLC	724,637	$1.02M	0.09%	00.0%	Unchanged
Stonepine Capital Management, LLC	695,287	$980.36K	0.75%	+31,875+4.8%	Added
VANGUARD CAPITAL MANAGEMENT LLC	88,865	$126.54K	0.00%	00.0%	Unchanged